Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of revenues in the USA following its approval. Mr Lee also clarifies Korea’s position within gene therapy R&D and explains Kolon’s strategy for lowering the cost of innovative gene therapy products.
Gene therapy is usually focused on rare disease. However, Kolon Life Science’s pipeline is not focused on rare disease, but more general disease. Our product, Invossa, is an exceptional case: it is focused on osteoarthritis which has a large patient population
